AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21593114 — intervention group
Group type: EXPERIMENTAL
Intervention: teriparatide (20 μg sc once daily)
Number of subjects: 569
Study 21593114 — intervention group
Group type: EXPERIMENTAL
Intervention: alendronate (70 mg once weekly)
Number of subjects: 569
Study 21593114 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 569
Study 19352048 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitiglinide 5 mg
Number of subjects: 381
Study 19352048 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitiglinide 10 mg
Number of subjects: 381
Study 19352048 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone monotherapy
Number of subjects: 381
Study 16333632 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg subcutaneous injection daily, initiated 12 hours preoperatively)
Number of subjects: 100
Study 16333632 — intervention group
Group type: COMPARATOR
Intervention: Heparin (5,000 IU subcutaneous standard heparin initiated 8 hours preoperatively, continued to 15,000 IU per day in three equal dosages every 8 hours)
Number of subjects: 100
Study 16333632 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Enoxaparin and Heparin
Number of subjects: 100
Study 16333632 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 100
Study 15587021 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading (same day of surgery)
Number of subjects: 19
Study 15587021 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading (next day after surgery)
Number of subjects: 19
Study 15587021 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall success rate
Number of subjects: 19
Study 11084176 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal 17 beta‐E2, 300 microg daily
Number of subjects: 361
Study 11084176 — intervention group
Group type: COMPARATOR
Intervention: Transdermal 17 beta‐E2 (delivering 50 microg/day), two patches per week
Number of subjects: 361
Study 9333058 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-dose chlorproguanil-dapsone
Number of subjects: 448
Study 9333058 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine-sulfadoxine
Number of subjects: 448
Study 9333058 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose chlorproguanil-dapsone
Number of subjects: 448
Study 9333058 — intervention group
Group type: COMPARATOR
Intervention: Community surveillance group
Number of subjects: 448
Study 8437527 — intervention group
Group type: EXPERIMENTAL
Intervention: SBT/AMP 1 g/2 g t.i.d. (n=35 clinically evaluable)
Number of subjects: 73
Study 8437527 — intervention group
Group type: COMPARATOR
Intervention: CXM 1.5 g t.i.d. (n=35 clinically evaluable)
Number of subjects: 73
Study 8437527 — intervention group
Group type: EXPERIMENTAL
Intervention: SBT/AMP (bacteriological efficacy assessed in 26 patients)
Number of subjects: 73
Study 8437527 — intervention group
Group type: COMPARATOR
Intervention: CXM (bacteriological efficacy assessed in 28 patients)
Number of subjects: 73
Study 2875812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2875812 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg bid)
Number of subjects: 24
Study 2875812 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (40 mg bid)
Number of subjects: 24
Study 29635061 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg phenylephrine tannate (equivalent to 10 mg phenylephrine HCl) combined with 200 mg guaifenesin, fasted
Number of subjects: 0
Study 29635061 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg phenylephrine HCl combined with 650 mg acetaminophen, fasted
Number of subjects: 0
Study 29635061 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg phenylephrine HCl, fed
Number of subjects: 0
Study 29635061 — intervention group
Group type: COMPARATOR
Intervention: 10 mg phenylephrine HCl, fasted (reference treatment)
Number of subjects: 0
Study 26616001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac nasal spray 31.5 mg
Number of subjects: 0
Study 26616001 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/ibuprofen 5/400 mg
Number of subjects: 0
Study 26616001 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone/APAP 7.5/500 mg
Number of subjects: 0
Study 26616001 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/APAP 5/325 mg
Number of subjects: 0
Study 26616001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac nasal spray
Number of subjects: 0
Study 26616001 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone/APAP 10/650 mg
Number of subjects: 0
Study 26616001 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol HCl/APAP 75/650 mg
Number of subjects: 0
Study 26616001 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol HCl/APAP 37.5/325 mg
Number of subjects: 0
Study 24585406 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2) and carboplatin (AUC=5) followed by gefitinib (250 mg/day) for 6 months
Number of subjects: 60
Study 24585406 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed (500 mg/m2) and carboplatin (AUC=5) alone
Number of subjects: 60
Study 23109900 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypes of ACAT‐1 AC, LIPC GA and AA, SCARB1 TT
Number of subjects: 1729
Study 23109900 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypes of ACAT‐1 CC; ACAT‐1 AA and CC
Number of subjects: 1729
Study 19832720 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (Pip-Tazo, n = 30)
Number of subjects: 62
Study 19832720 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin (IMP, n = 32)
Number of subjects: 62
Study 18677201 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: early scan (image acquisition initiated within 15 min after injection of the tracer) and no food
Number of subjects: 152
Study 18677201 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D: late scan (image acquisition 30‐60 min after injection of the tracer) and food (two pieces of white bread with butter and a minimum of 450 ml of water)
Number of subjects: 152
Study 18677201 — intervention group
Group type: COMPARATOR
Intervention: Early scan (Group A)
Number of subjects: 152
Study 18677201 — intervention group
Group type: COMPARATOR
Intervention: Addition of food (Group D)
Number of subjects: 152
Study 18677201 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest MPI in 116 of 152 patients
Number of subjects: 152
Study 16061592 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg per day for 1 week)
Number of subjects: 287
Study 16061592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 16061592 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 287
Study 12382302 — intervention group
Group type: EXPERIMENTAL
Intervention: Care provided by a clinical nurse specialist
Number of subjects: 210
Study 12382302 — intervention group
Group type: COMPARATOR
Intervention: Inpatient team care
Number of subjects: 210
Study 12382302 — intervention group
Group type: COMPARATOR
Intervention: Day patient team care
Number of subjects: 210
Study 12953977 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg gossypol tablet daily until azoospermia occurred, followed by a maintenance dose of 7.5 mg or 10 mg of gossypol orally to alternate subjects.
Number of subjects: 13
Study 8669221 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil bolus of 15 micrograms
Number of subjects: 24
Study 8669221 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil bolus of 30 micrograms
Number of subjects: 24
Study 8669221 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil bolus of 45 micrograms
Number of subjects: 24
Study 8669221 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of sufentanil of 15 micrograms/h
Number of subjects: 24
Study 8669221 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of sufentanil of 30 micrograms/h
Number of subjects: 24
Study 8669221 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of sufentanil of 45 micrograms/h
Number of subjects: 24
Study 2148735 — intervention group
Group type: EXPERIMENTAL
Intervention: Chandonium iodide 0.2 mg/kg
Number of subjects: 50
Study 2148735 — intervention group
Group type: EXPERIMENTAL
Intervention: Chandonium iodide 0.25 mg/kg
Number of subjects: 50
Study 6895645 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 24
Study 6895645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31727347 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese square dancing (12-week routine)
Number of subjects: 66
Study 31727347 — intervention group
Group type: COMPARATOR
Intervention: Usual lifestyle (control group)
Number of subjects: 66
Study 29158123 — intervention group
Group type: EXPERIMENTAL
Intervention: Necitumumab continuation therapy
Number of subjects: 476
Study 29158123 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine-cisplatin nonprogressors
Number of subjects: 476
Study 26740030 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based learning (TBL)
Number of subjects: 63
Study 26740030 — intervention group
Group type: COMPARATOR
Intervention: Control group (lectures and traditional case study)
Number of subjects: 63
Study 23980620 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose stavudine (30-40 mg)
Number of subjects: 60
Study 23980620 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose stavudine (20-30 mg)
Number of subjects: 60
Study 23980620 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (300 mg)
Number of subjects: 60
Study 22914501 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% diquafosol ophthalmic solution
Number of subjects: 286
Study 22914501 — intervention group
Group type: COMPARATOR
Intervention: 0.1% sodium hyaluronate ophthalmic solution
Number of subjects: 286
Study 19740116 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg twice daily
Number of subjects: 41
Study 19740116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 17493710 — intervention group
Group type: EXPERIMENTAL
Intervention: Flu vaccine plus 10 microg IMP321
Number of subjects: 60
Study 17493710 — intervention group
Group type: EXPERIMENTAL
Intervention: Flu vaccine plus 30 microg IMP321
Number of subjects: 60
Study 17493710 — intervention group
Group type: EXPERIMENTAL
Intervention: Flu vaccine plus 100 microg IMP321
Number of subjects: 60
Study 17493710 — intervention group
Group type: COMPARATOR
Intervention: Flu vaccine plus saline control
Number of subjects: 60
Study 16179039 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon (Xe, n = 20)
Number of subjects: 39
Study 16179039 — intervention group
Group type: COMPARATOR
Intervention: Total Intravenous Anaesthesia (TIVA, n = 19)
Number of subjects: 39
Study 16179039 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon (Xe)
Number of subjects: 39
Study 16179039 — intervention group
Group type: COMPARATOR
Intervention: TIVA
Number of subjects: 39
Study 11823399 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl
Number of subjects: 32
Study 11823399 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl
Number of subjects: 32
Study 10488703 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic banding ligation
Number of subjects: 127
Study 10488703 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 127
Study 9036477 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (administered up to 40 micrograms/kg/min, and atropine when necessary)
Number of subjects: 74
Study 9036477 — intervention group
Group type: COMPARATOR
Intervention: Exercise stress test
Number of subjects: 74
Study 1713985 — intervention group
Group type: EXPERIMENTAL
Intervention: benazepril 10 mg twice daily (b.i.d.) for 2 weeks
Number of subjects: 11
Study 1713985 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study 6134884 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoccult faecal occult blood testing
Number of subjects: 20525
Study 6134884 — intervention group
Group type: COMPARATOR
Intervention: Control group (no testing)
Number of subjects: 20525
Study 6134884 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibreoptic sigmoidoscopy
Number of subjects: 20525
Study 6134884 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-contrast barium enema
Number of subjects: 20525
Study 30833377 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 0
Study 30833377 — intervention group
Group type: COMPARATOR
Intervention: Control (no epinephrine)
Number of subjects: 0
Study 29364729 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth emotion mind-sets induction
Number of subjects: 630
Study 29364729 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth emotion mind-sets and failure-is-enhancing beliefs induction
Number of subjects: 630
Study 29364729 — intervention group
Group type: COMPARATOR
Intervention: No induction
Number of subjects: 630
Study 26749431 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face strategy
Number of subjects: 288
Study 26749431 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mail strategy
Number of subjects: 288
Study 26749431 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 288
Study 25567831 — intervention group
Group type: EXPERIMENTAL
Intervention: iPhone application (DizzyFIX)
Number of subjects: 0
Study 25567831 — intervention group
Group type: COMPARATOR
Intervention: Sham application
Number of subjects: 0
Study 22627983 — intervention group
Group type: EXPERIMENTAL
Intervention: STeleR intervention (3 home visits, 5 telephone calls, in-home messaging device over 3 months)
Number of subjects: 52
Study 22627983 — intervention group
Group type: EXPERIMENTAL
Intervention: STeleR intervention
Number of subjects: 52
Study 22627983 — intervention group
Group type: COMPARATOR
Intervention: Usual care (routine rehabilitation care as prescribed by physicians)
Number of subjects: 52
Study 20400183 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (newborns exposed to tactile communication)
Number of subjects: 20
Study 20400183 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (newborns without communication)
Number of subjects: 20
Study 20400183 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphonic Cry
Number of subjects: 20
Study 20400183 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperphonic Cry
Number of subjects: 20
Study 18827129 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 194
Study 15886989 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery in patients with PEX; 171 out of 370 cataract eyes had PEX; 68% had preoperative complications including 89 subluxations, 15 vitreous prolapses, 6 ciliolenticular blocks, and 7 intravitreal dislocations.
Number of subjects: 370
Study 15886989 — intervention group
Group type: COMPARATOR
Intervention: Cataract surgery in Omani cataract eyes without PEX; 40 eyes evaluated; endothelial cell count normal compared to age-matched US norm; corneal thickness less than Caucasians but more than Afro-Americans.
Number of subjects: 370
Study 11913804 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (30 mg kg(‐1) bolus followed by 0.5 g h(‐1) infusion for 20 hours)
Number of subjects: 24
Study 11913804 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution (same volume as magnesium)
Number of subjects: 24
Study 10527970 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Laparoscopic Hysterectomy (TLH)
Number of subjects: 235
Study 10527970 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 235
Study 10527970 — intervention group
Group type: COMPARATOR
Intervention: Vaginal Hysterectomy
Number of subjects: 235
Study 7781666 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard activity of 555 MBq 131iodine
Number of subjects: 205
Study 7781666 — intervention group
Group type: COMPARATOR
Intervention: Calculated activity to deliver 100 Gy
Number of subjects: 205
Study 7781666 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation dose absorbed by the thyroid
Number of subjects: 205
Study 2031797 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol 140 mg I/ml (300 mosm/kg H2O)
Number of subjects: 12
Study 2031797 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol 300 mg I/ml (690 mosm/kg H2O)
Number of subjects: 12
Study 2031797 — intervention group
Group type: COMPARATOR
Intervention: diatrizoate 292 mg I/ml (1480 mosm/kg H2O)
Number of subjects: 12
Study 6628650 — intervention group
Group type: EXPERIMENTAL
Intervention: Spouse‐aided therapy
Number of subjects: 53
Study 6628650 — intervention group
Group type: COMPARATOR
Intervention: Individual therapy
Number of subjects: 53
Study 31163544 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretion-free group
Number of subjects: 228
Study 31163544 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal bacteria group (oral cavity and skin)
Number of subjects: 228
Study 31163544 — intervention group
Group type: EXPERIMENTAL
Intervention: Single non-resistant bacteria group
Number of subjects: 228
Study 31163544 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungal group
Number of subjects: 228
Study 31163544 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound or multi-drug resistant bacteria group
Number of subjects: 228
Study 31163544 — intervention group
Group type: COMPARATOR
Intervention: All groups compared to compound or multi-drug resistant bacteria group
Number of subjects: 228
Study 31163544 — intervention group
Group type: COMPARATOR
Intervention: Fungal group compared to non-drug resistant bacteria, normal oral and skin flora, and secretion-free group
Number of subjects: 228
Study 31163544 — intervention group
Group type: COMPARATOR
Intervention: Different preoperative secretions classification
Number of subjects: 228
Study 28633409 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 28633409 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 0
Study 28633409 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 28633409 — intervention group
Group type: COMPARATOR
Intervention: PD-L1 testing
Number of subjects: 0
Study 25677311 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated bifurcation stent
Number of subjects: 704
Study 25677311 — intervention group
Group type: COMPARATOR
Intervention: Provisional stenting
Number of subjects: 704
Study 24497205 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg
Number of subjects: 50
Study 24497205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23020650 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 75 μg once-daily
Number of subjects: 322
Study 23020650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 19664404 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 10917
Study 19664404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10917
Study 17504339 — intervention group
Group type: EXPERIMENTAL
Intervention: PPH with additional surgical intervention
Number of subjects: 310
Study 17504339 — intervention group
Group type: COMPARATOR
Intervention: Conventional haemorrhoidectomy
Number of subjects: 310
Study 16941069 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalvometer (forced expiration through a flow restriction device)
Number of subjects: 100
Study 16941069 — intervention group
Group type: COMPARATOR
Intervention: Traditional Valsalva manoeuvre (following standardised verbal instruction)
Number of subjects: 100
Study 14971530 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative vaginal douching with 1 per cent povidone-iodine
Number of subjects: 300
Study 14971530 — intervention group
Group type: COMPARATOR
Intervention: Control (no vaginal douching)
Number of subjects: 300
Study 11005562 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy with 60 MBq 99mTc‐nanocolloid (1.6 mCi)
Number of subjects: 200
Study 11005562 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy
Number of subjects: 200
Study 9097895 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (50, 100, and 200 mg)
Number of subjects: 10
Study 9097895 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (10 mg)
Number of subjects: 10
Study 9097895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8474402 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 g fish oil (3.15 g n-3 fatty acids per day)
Number of subjects: 0
Study 8474402 — intervention group
Group type: COMPARATOR
Intervention: 9 g olive oil
Number of subjects: 0
Study 3546166 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (diferuloyl methane)
Number of subjects: 0
Study 3546166 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutazone
Number of subjects: 0
Study 3546166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30993341 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic trace minerals (OTM) supplementation
Number of subjects: 128
Study 30993341 — intervention group
Group type: COMPARATOR
Intervention: Inorganic trace minerals (ITM) supplementation
Number of subjects: 128
Study 30993341 — intervention group
Group type: EXPERIMENTAL
Intervention: Progeny of OTM-fed breeders
Number of subjects: 128
Study 30993341 — intervention group
Group type: COMPARATOR
Intervention: Progeny of ITM-fed breeders
Number of subjects: 128
Study 28698009 — intervention group
Group type: EXPERIMENTAL
Intervention: epacadostat 600mg
Number of subjects: 42
Study 28698009 — intervention group
Group type: COMPARATOR
Intervention: tamoxifen 20mg
Number of subjects: 42
Study 28698009 — intervention group
Group type: EXPERIMENTAL
Intervention: epacadostat
Number of subjects: 42
Study 28698009 — intervention group
Group type: COMPARATOR
Intervention: tamoxifen
Number of subjects: 42
Study 25726399 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum oxide discs (n = 10)
Number of subjects: 10
Study 25726399 — intervention group
Group type: COMPARATOR
Intervention: Multilaminated carbide burs (n = 10)
Number of subjects: 10
Study 23140805 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy (MDFT)
Number of subjects: 0
Study 23140805 — intervention group
Group type: COMPARATOR
Intervention: Individual Psychotherapy (IP)
Number of subjects: 0
Study 21954640 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0